The Wnt signalling pathway balances the opposing activities of two proteins to transmit signals within cells. An inhibitor that stabilizes one of these proteins reveals a new target for anticancer drug development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Powell, S. M. et al. Nature 359, 235–237 (1992).
Huang, S.-M. A. et al. Nature 462, 614–620 (2009).
Tolwinski, N. S. & Wieschaus, E. Trends Genet. 20, 177–181 (2004).
Barker, N. & Clevers, H. Nature Rev. Drug Discov. 5, 997–1014 (2006).
Chen, B. et al. Nature Chem. Biol. 5, 100–107 (2009).
Hsiao, S. J. & Smith, S. Biochimie 90, 83–92 (2008).
Chiang, Y. J. et al. PLoS ONE 3, e2639 (2008).
Seimiya, H. Br. J. Cancer 94, 341–345 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peterson, R. Propping up a destructive regime. Nature 461, 599–600 (2009). https://doi.org/10.1038/461599a
Published:
Issue Date:
DOI: https://doi.org/10.1038/461599a
This article is cited by
-
Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks
The Pharmacogenomics Journal (2011)